Invasight

Invasight is a Swiss-based early-clinical stage biotech start-up. Our breakthrough technology, ACINDA accelerates drug discovery and enables design of specific protein-protein interaction antagonists (PPIAs) for non-traditional intercellular protein targets, which cause cancer cell invasion. Our first-in-class PPIAs combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers. The most advanced of these first-in-class, protein-protein interaction antagonists is F2i, a inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.